Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytyc

This article was originally published in The Gray Sheet

Executive Summary

Prudential Health Plans joins a growing list of third party payers that are reimbursing for the ThinPrep Pap Test for cervical cancer screening, the company told investors at a June 9 Piper Jaffray conference in Minneapolis. The test, which sells at a list price of $475 for 40 tests, has been accepted for reimbursement by independent Blue Cross and Blue Shield health plans in New York (Empire), North Carolina, Maryland, Montana, and West Virginia (Mountain State) and by Oxford Health Plans. Pennsylvania-based Highmark Blue Cross and Blue Shield rejected a reimbursement request by Cytyc earlier this year citing a lack of evidence to demonstrate cost effectiveness of the device ("The Gray Sheet" Feb. 16, p. 9). Cytyc is considering seeking labeling to allow for screening for common sexually transmitted diseases
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT010185

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel